GlassScriptPhysician profile
Jonathan T Feist
NPI 1427462969
$813.02
in general payments reported to CMS, 2019-2025
19 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $164 · 2024: $190 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $119.78 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $112.51 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $97.17 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $82.14 | 2025 | Fanapt |
| Abbott Laboratories | $53.00 | 2024-2025 | Freestyle Libre 3 |
| Biogen, INC. | $46.31 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $39.44 | 2023 | Belsomra, Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $35.74 | 2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $32.53 | 2024 | Farxiga |
| Xeris Pharmaceuticals, INC. | $28.78 | 2023-2024 | Gvoke Hypopen |
| Pfizer INC. | $27.07 | 2023 | |
| Daiichi Sankyo INC. | $24.64 | 2025 | Injectafer |
| Inspire Medical Systems, INC. | $18.45 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $17.26 | 2025 | |
| Amgen INC. | $17.20 | 2023 | Prolia, Evenity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16.35 | 2025 | Mounjaro, Zepbound |
| Abiomed | $15.73 | 2025 | |
| Verona Pharma, INC. | $15.37 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $13.55 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Feist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.